Cargando…
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants...
Autor principal: | Maraganore, Demetrius M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Movement Disorder Society
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027709/ https://www.ncbi.nlm.nih.gov/pubmed/24868385 http://dx.doi.org/10.14802/jmd.11001 |
Ejemplares similares
-
In vivo silencing of alpha-synuclein using naked siRNA
por: Lewis, Jada, et al.
Publicado: (2008) -
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022) -
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021) -
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022) -
Transmission of alpha-synuclein in Parkinson’s disease
por: Lee, Virginia M-Y
Publicado: (2013)